CERO THERAPEUTICS HOLDINGS, INC. (CERO): Nasdaq/NYSE listing notice — Phoenix Biotech receives Nasdaq deficiency notice for minimum public holders rule

CERO THERAPEUTICS HOLDINGS, INC.

Received Nasdaq notice on Sep 7, 2023, for non-compliance with Minimum Public Holders Rule (400 public holders required for Nasdaq Global Market).
Has 45 calendar days to submit a plan to regain compliance; intends to submit within timeframe.
If plan accepted, Nasdaq may grant up to 180-day extension; if rejected, can appeal to Hearings Panel.
Also pursuing a business combination with CERo Therapeutics (previously filed Form S-4).
Notice is not an imminent delisting; no current effect on listing or trading of PBAX securities.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding other (rules 5450(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Rules: 5450(a)(2)

Exact text from the filing

September 7, 2023, Phoenix Biotech Acquisition Corp., a Delaware corporation (the “Company”), received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company was not in compliance with Listing Rule 5450(a)(2), which requires the Company to have at least 400 public holders for continued listing on the Nasdaq Global Market (the “Minimum Public Holders Rule”). The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s se

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

CERO THERAPEUTICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-075416

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.